ACADIA Pharmaceuticals shares plunge 22% as analysts adjust targets
The Nasdaq-listed biotech lost nearly a quarter of its value in the latest session despite peers in the health care sector rising.
The Nasdaq-listed biotech lost nearly a quarter of its value in the latest session despite peers in the health care sector rising. Published 2026-11-09 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
ACADIA Pharmaceuticals Inc. shares fell 22.28% on Monday to trade at $16.50, erasing gains made earlier in the week. The drop left the stock 46.0% below its 52-week high of $30.96.
Analyst target revisions
Deutsche Bank adjusted its price target for ACADIA Pharmaceuticals to $30 from $31, maintaining a Buy rating, according to MT Newswires. RBC raised its price target to $41 from $31, keeping an Outperform rating, the same source reported.
The company announced it will present data on remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference. Two data presentations related to Alzheimer's disease psychosis and remlifanserin are scheduled for the event.
Market underperformance
The sell-off occurred while the broader market rose. The S&P 500 gained 2.4% and the US Health Care sector (XLV) increased 1.9% in the same session.
Falling Shares attributed 23.8% of the session's movement to company-specific factors, compared to 1.9% from the market and -0.3% from the sector. The stock has fallen 19.4% over five days and 16.6% over the past month.
Volatility and trends
Falling Shares rates the stock Unstable, citing an annualised volatility of 66.2% versus 14.5% for the benchmark. The stock has recorded six sessions with moves of 5% or more in the past six months.
Technical indicators show the long-term trend is weakening, with the price 29.8% below the 200-day average. The 50-day average has fallen below the 200-day average, forming a death cross.